1310
document
Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol . A multicenter , randomized comparison of levonorgestrel/ethinyl estradiol ( 100 micrograms/20 micrograms ) and norethindrone/ethinyl estradiol ( 1000 micrograms/20 micrograms ) . A randomized , open-label , multicenter study was undertaken to compare the effects of oral contraceptives ( OC ) containing 100 micrograms levonorgestrel ( LNG ) /20 micrograms ethinyl estradiol ( EE ) ( Aless/Loette ) and 1000 micrograms norethindrone acetate ( NETA ) /20 micrograms EE ( Loestrin Fe 1/20 ) on menstrual cycle control over four cycles of use . A total of 84 evaluable women provided 274 cycles of exposure in the LNG/EE group , and 89 women provided 289 cycles of exposure in the NETA/EE group . Overall , the LNG/EE group achieved a consistently higher percentage of normal menstrual cycles as well as a lower rate of intermenstrual bleeding and amenorrhea than the NETA/EE group . In cycle 4 , 63.8 % of cycles were normal in the LNG/EE group compared with 41.9 % in the NETA/EE group ( p < 0.005 ) . Of the total cycles in the NETA/EE group , 10 % were amenorrheic , compared with 1.1 % in the LNG/EE group . The occurrence of bleeding and/or spotting was significantly lower in cycles 2 and 3 in the LNG/EE group ( 41.7 % and 34.8 % , respectively ) compared with the NETA/EE group ( 62.3 % and 56.3 % ; p < 0.05 ) . Other cycle variables were generally similar between groups , as was the incidence of adverse events . These results demonstrate that good cycle control was achieved with an OC containing 20 micrograms EE and that 100 micrograms LNG/20 micrograms EE produces better cycle control than 1000 micrograms NETA/20 micrograms EE .
1311
Intervention_Pharmacological
oral contraceptives containing 20 micrograms of ethinyl estradiol .
1312
Intervention_Pharmacological
levonorgestrel/ethinyl estradiol
1313
Intervention_Pharmacological
norethindrone/ethinyl estradiol
1314
Intervention_Pharmacological
oral contraceptives ( OC ) containing 100 micrograms levonorgestrel ( LNG ) /20 micrograms ethinyl estradiol ( EE ) ( Aless/Loette )
1315
Intervention_Pharmacological
1000 micrograms norethindrone acetate ( NETA ) /20 micrograms EE ( Loestrin Fe 1/20 )
1316
Intervention_Pharmacological
EE
1317
Intervention_Pharmacological
LNG/20
1318
Intervention_Pharmacological
NETA/20
1319
Outcome_Physical
percentage of normal menstrual cycles
1320
Outcome_Physical
rate of intermenstrual bleeding and amenorrhea
1321
Outcome_Physical
amenorrheic
1322
Outcome_Physical
occurrence of bleeding and/or spotting
1323
Outcome_Adverse-effects
adverse events
1324
Participant_Sample-size
84 evaluable
1325
Participant_Sex
women
1326
Participant_Sample-size
89 women